ST
Sinja Taavitsainen
Research areas: Biochemistry, Genetics and Molecular Biology · Cancer Research · Cancer Genomics and Diagnostics · Prostate Cancer Treatment and Research · Chromatin Remodeling and Cancer
0000-0001-7559-9853
Employment
Employment history is unavailable.
Education
Education history is unavailable.
Projects & Funding
Projects & funding information is unavailable.
Publications (21)
- Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer Save
- Single cell and spatial transcriptomics highlight the interaction of club-like cells with immunosuppressive myeloid cells in prostate cancer Save
- Cancer origin tracing and timing in two high-risk prostate cancers using multisample whole genome analysis: prospects for personalized medicine Save
- Fanconi anemia pathway regulation by FANCI in prostate cancer Save
- Estimation of tumor cell total mRNA expression in 15 cancer types predicts disease progression Save
- Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial Save
- Chromatin and epigenetic dysregulation of prostate cancer development, progression, and therapeutic response Save
- Combined longitudinal clinical and autopsy phenomic assessment in lethal metastatic prostate cancer: recommendations for advancing precision medicine Save
- Evolution of castration-resistant prostate cancer in ctDNA during sequential androgen receptor pathway inhibition Save
- Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer Save
- Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse Save
- Subclone eradication analysis identifies targets for enhanced cancer therapy and reveals L1 retrotransposition as a dynamic source of cancer heterogeneity Save
- Activating AKT1 and PIK3CA mutations in metastatic castration-resistant prostate cancer Save
- HSD3B1 (1245A> C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies Save
- Identification of hypermutation and defective mismatch repair in ctDNA from metastatic prostate cancer Save
- Prostate cancer evolution from multilineage primary to single lineage metastases with implications for liquid biopsy Save
- Evaluation of commercial circulating tumor DNA test in metastatic prostate cancer Save
- Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial Save
- Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer Save
- Frequent mutation of the FOXA1 untranslated region in prostate cancer Save